Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176252 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects
A Phase 1 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT02176252 is a Phase 1 study that has completed, run by Ardelyx. The registered enrollment target is 83 participants.
The verdict
NCT02176252, a Phase 1 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects.
Interventions
- DRUG Placebo
- DRUG AZD1722
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176252
The ClinicalTrials.gov registry entry for NCT02176252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02176252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02176252 about?
NCT02176252 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects". The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included i...
What is the current status of trial NCT02176252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2013-07. Estimated completion is 2013-12.
What interventions are being tested in trial NCT02176252?
The interventions under investigation include: Placebo (DRUG), AZD1722 (DRUG).
Who is sponsoring clinical trial NCT02176252?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.